Business
A Credit Suisse study finds that most hostile bids fail, especially if antitrust concerns are involved.
Hi, what are you looking for?
Jewish Business News
Business
Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, are pushing Mylan to take Teva’s $40 billion take-over bid offer seriously.
Business
Lyra Health, aims to tackle behavioral healthcare; backed by VC firm Venrock
Business
Opko Health Inc. (NYSE: OPK; TASE: OPK), has agreed to buy Bio-Reference Laboratories Inc.(Nasdaq: BRLI) in a deal valued at about $1.5 billion. Opko said...
Business
In the three way takeover battle Mylan is getting nervous.
Business
Three Way Takeover Battle: believes their offer will win approval from Perrigo stockholders.
Business
Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon...
Business
Teva Pharmaceutical Industries Ltd, an Israeli-based company, has acquired a 1.35 percent stake in Mylan through purchases on the open market, increasing pressure on...
Business
Perrigo Company (NYSE:PRGO; TASE:PRGO) CEO Joseph Papa is ready to talk with Mylan N.V. (MYL) about its takeover bid, but at a higher price....
Business
Teva CFO Eyal Desheh told Merrill Lynch that it could secure antitrust clearance for the takeover in 4-7 months.